Evidence map›Paper›PMID 19559666›Full record

ArticleBiochimica et biophysica acta2009

Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids.

Raquel F Epand, Vinod K Mishra, Mayakonda N Palgunachari, G M Anantharamaiah, Richard M Epand

Abstract read
In one paragraph

Article in Biochimica et biophysica acta, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. HDL Mimetic Peptides.Advances in experimental medicine and biology · 2022
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Raquel F EpandDepartment of Biochemistry and Biomedical Sciences, McMaster University Health Science Center, Hamilton, Ontario, Canada L8N 3Z5. epand@mcmaster.ca
Vinod K Mishra
Mayakonda N Palgunachari
G M Anantharamaiah
Richard M Epand
University of Alabama at Birmingham · USMcMaster University Medical Centre · CA

Funding

SYNTHETIC PEPTIDE STUDIES OF THE AMPHIPATHIC HELIXP01HL034343 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SEGREST, JERE P · 1985 to 2012
$18.8M
Enhanced Hepatic Lipoprotein Uptake and AtherogenesisR01HL065663 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANANTHARAMAIAH, G M · 2001 to 2004
$1.4M
NHLBI NIH HHS P01 HL034343NHLBI NIH HHS R01 HL065663PHS HHS NIHHL 34343
6 · The paper itself

Abstract

The peptide 4F is known to have potent anti-atherogenic activity. 4F is an 18 residue peptide that has a sequence capable of forming a class A amphipathic helix. Several other class A amphipathic helical, 18 residue peptides with the same polar face but with increasing Phe residues on the nonpolar face have been synthesized with varying degrees of biological activity. In this work we compared the properties of the original 2F peptide, modeled on the consensus sequence of the amphipathic helical segments of the apolipoprotein A-I with the peptide 4F that has two Leu residues replaced with Phe. We demonstrate that the more biologically active 4F peptide has the greatest affinity for binding to several molecular species of oxidized lipids. Lipoprotein particles can be formed by solubilizing 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) with peptides. These solubilized lipoprotein particles extract oxidized lipid from liposomes of POPC containing 5 mol% of oxidized lipid. The peptides with the strongest anti-atherogenic activity interact most strongly with the oxidized lipid. The results show that there is a correlation between the biological potency of these peptides and their ability to interact with certain specific cytotoxic lipids, suggesting that this interaction may contribute favourably to their biological properties.

Indexed as

Anti-Inflammatory AgentsAtherosclerosisCalorimetry, Differential ScanningLipid BilayersLipidsOxidation-ReductionPeptidesPhosphatidylcholinesPhospholipid EthersPhosphorylcholine1-0-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocoline1-palmitoyl-2-(4-ketododec-3-enedioyl)phosphatidylcholine1-palmitoyl-2-(5-keto-6-octenedioyl)phosphatidylcholine1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholineAnti-Inflammatory AgentsLipid BilayersLipidsPeptidesPhosphatidylcholinesPhospholipid EthersPhosphorylcholine

Identifiers

PMID19559666
PMCPMC2768607
OpenAlexW1996108576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.